FEB 25, 2019 10:49 AM PST

Largest Alzheimer's Study to Test New Drug

WRITTEN BY: Amy Loriaux

In the largest planned study to examine the effects of a new Alzheimer's Disease (AD) treatment is underway. It will involve 40 sites across the country. Some of the notable sites include Yale University School of Medicine; Northwestern University; the University of California San Diego; University of Michigan, Ann Arbor; University of Kentucky; University of Pittsburgh; and Johns Hopkins University, to name a few. The clinical studies are being coordinated through UC San Diego's Alzheimer's Disease Cooperative Study (ADCS) headed by Dr. Howard Feldman, MD.  

Photo source: Pixabay.com

The official name of this colossal undertaking is T2 Protect AD and is still accepting volunteers. To sign up you can go to www.t2protect.org. The project should take a year for each participant, or, as Dr. Feldman told KPBS News, “We are examining for benefits in cognitive function and thinking and memory over the course of one year.” He went on to say, " We’re aiming to achieve somewhere of about a 40 percent reduction in what would typically happen to a person over this period of time.”

The drug being tested is a compound called toriluzole (BHV-4157), developed by Biohaven Pharmaceuticals. Toriluzole was developed by Biohaven's glutamate platform. It is designed to balance the glutamate system through glutamate transporter modulation. One school of thought suggests that AD, as well as other neurodegenerative diseases, such as ALS, is due to too much glutamate in the synapse. Because this can cause excitotoxicity (which kills neurons), the idea is that by restoring the glutamate balance you can slow or even reverse symptoms of AD.

Photo sourcePixabay.com

Preclinical investigations have lent credence to the idea that excess glutamate could cause some if not all of the symptoms of AD. For instance, one study showed that excess glutamate in the synapse, due to ineffective glutamate transporters (GLT-1) in genetically engineered mice, produced AD-like symptoms. Another study revealed that restoring glutamate transporters in mouse models of AD significantly improved cognitive functions, restored synaptic integrity, and reduced amyloid plaques.

Previous attempts based on different scientific hypotheses for the etiology, progression, and fatality of AD have helped, but not cured, AD patients. Cholinesterase (the enzyme that breaks down acetylcholine) inhibitors are used based on the theory that AD is due to deficits in the cholinergic system. Vitamin E supplements, exercise, and cognitive stimulation have also been used to slow cognitive decline in AD patients. Biohaven has recently presented their rationale for their Phase II / Phase III clinical trials at the 11th conference of Clinical Trials on Alzheimer's Disease (CTAD). If these studies prove promising we may have a new weapon in our arsenal against AD.

Below is a very brief video going into more depth about how glutamate neurons could become excitotoxic. The video focuses on stroke, which is the definite cause of glutamate excitotoxicity in this case. Scientists are not sure what leads to glutamate excitotoxicity in AD, but the process would essentially lead to the same consequences.

Video source: YouTube.com

Source: www.adcs.orgwww.biohavenpharma.com, Translational Psychiatry, www.t2protect.org, KPBS News, Journal of Alzheimers Disease, Journal of Experimental Medicine, American Family Physician

About the Author
  • I currently work at a small CRO involved in clinical trial management.
You May Also Like
NOV 26, 2019
Neuroscience
NOV 26, 2019
Air Pollution Linked to Alzheimer's, Study Finds
Worldwide, 9 in every 10 people breathe highly polluted air. A known contributing factor for many respiratory illnesses such as lung cancer, an increasing ...
NOV 27, 2019
Neuroscience
NOV 27, 2019
ADHD and Autism Share the Same Genes
In the US, 1 in every 59 children has autism, with 1 in every 20 having ADHD. Now, researchers from Denmark’s national psychiatric project, iPSYCH, h...
DEC 01, 2019
Neuroscience
DEC 01, 2019
Are teens addicted to their phones?
Journalists quickly jumped to the conclusion that 23% of teenagers are addicted to their smartphones thanks to findings from a new study from King’s ...
DEC 20, 2019
Drug Discovery & Development
DEC 20, 2019
Drug Repurposing May Provide Hope for Deadly Childhood Seizure Disorder
The life-threatening and treatment-resistant seizure disorder among children known as the ‘Dravet Syndrome’ may soon have new safe and effectiv...
JAN 13, 2020
Neuroscience
JAN 13, 2020
A Quarter of Children with Autism are Left Undiagnosed
Researchers from Rutgers University have found that 25% of children under the age of 8 with autism in the US are left undiagnosed, something that may be a ...
FEB 06, 2020
Cell & Molecular Biology
FEB 06, 2020
Taking a Closer Look at a Disease-Linked Protein
Misfolded proteins are closely linked to many neurodegenerative disorders. Researchers have learned more about one of those pathogenic proteins....
Loading Comments...